EMAIL THIS PAGE TO A FRIEND

Neuropharmacology

Monoamine receptor agonists, acting preferentially at presynaptic autoreceptors and heteroreceptors, downregulate the cell fate adaptor FADD in rat brain cortex.


PMID 25286119

Abstract

FADD is a crucial adaptor of death receptors that can engage apoptosis or survival actions (e.g. neuroplasticity) through its phosphorylated form (p-FADD). Although FADD was shown to participate in receptor mechanisms related to drugs of abuse, little is known on its role in the signaling of classic neurotransmitters (dopamine, noradrenaline, and serotonin) in brain. This study assessed the modulation of FADD (and p-FADD/FADD ratio, as an index of neuroplasticity) and FLIP-L (a neuroprotective FADD interacting partner), as well as the role of MEK-ERK signaling, after activation of monoamine auto/heteroreceptors by selective agonists in rat cortex. Acute depletion of monoamines with reserpine, but not with AMPT or PCPA, reduced FADD (28%) and increased p-FADD/FADD ratio (1.34-fold). Activation of presynaptic α2A-adrenoceptors (UK-14304 and clonidine), 5-HT1A receptors (8-OH-DPAT), and D2 dopamine receptor (bromocriptine) dose-dependently decreased FADD (up to 54%) and increased p-FADD (up to 29%) and p-FADD/FADD ratios (up to 2.93-fold), through specific receptor mechanisms. Activation of rat 5-HT1B autoreceptor in axon terminals by CP-94253 did not modulate FADD forms. Activation of postsynaptic D1 dopamine receptor by SKF-81297 also reduced FADD (25%) and increased p-FADD (32%). Disruption of MEK-ERK activation with SL327 did not modify clonidine (α2A-adrenoceptor)-induced FADD inhibition, indicating that agonist effect was not dependent on ERK signaling. The various monoamine receptor agonists and antagonists did not alter FLIP-L content, or the activation of executioner caspase-3 and PARP-1 cleavage, indicating that the agonists attenuated apoptotic signals and promoted neuroplasticity through FADD regulation. These novel results indicate that inhibition of pro-apoptotic FADD adaptor could function as a common signaling step in the initial activation of monoamine receptors in the brain.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

149837
2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, ≥99%
C14H17NO3
C6506
4-Chloro-DL-phenylalanine
C9H10ClNO2
120693
α-Methyl-DL-tyrosine, 98%
C10H13NO3
Y0001465
Apomorphine hydrochloride hemihydrate, European Pharmacopoeia (EP) Reference Standard
C17H17NO2 · HCl · 0.5H2O
B-008
Benzoylecgonine-d3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C16D3H16NO4
B-001
Benzoylecgonine-d3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material
C16D3H16NO4
B19401
Benzyl cyanide, 98%
C8H7N
C7897
Clonidine hydrochloride, solid
C9H9Cl2N3 · HCl
C2400000
Clonidine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C9H9Cl2N3 · HCl
78040
DL-Phenylalanine, puriss., ≥99.0% (NT)
C9H11NO2
W372609
DL-Phenylalanine, 99%, FCC
C9H11NO2
147966
DL-Phenylalanine, ReagentPlus®, 99%
C9H11NO2
339245
Hydrobromic acid, 48 wt. % in H2O, ≥99.99%
HBr
438065
Hydrobromic acid, ACS reagent, 48%
HBr
244260
Hydrobromic acid, ACS reagent, 48%
HBr
268003
Hydrobromic acid, reagent grade, 48%
HBr
18720
Hydrobromic acid solution, purum p.a., ≥62% (T)
HBr
18735
Hydrobromic acid solution, 33 wt. % in acetic acid
HBr
295418
Hydrogen bromide, ReagentPlus®, ≥99%
HBr
248630
Hydrogen bromide solution, 33 wt. % in acetic acid
HBr
P1150000
Phenylalanine, European Pharmacopoeia (EP) Reference Standard
C9H11NO2
A4393
R-(−)-Apomorphine hydrochloride hemihydrate, calcined, ≥98.5%
C17H17NO2 · HCl · 0.5H2O
R0875
Reserpine
C33H40N2O9
83580
Reserpine, crystallized, ≥99.0% (HPLC)
C33H40N2O9
R0200000
Reserpine, European Pharmacopoeia (EP) Reference Standard
C33H40N2O9
43530
Reserpine Standard for LC-MS, analytical standard, for LC-MS
C33H40N2O9